Novavax, Inc. (NVAX)
NVAX Stock Price Chart
Explore Novavax, Inc. interactive price chart. Choose custom timeframes to analyze NVAX price movements and trends.
NVAX Company Profile
Discover essential business fundamentals and corporate details for Novavax, Inc. (NVAX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Dec 1995
Employees
749.00
Website
https://www.novavax.comCEO
John Charles Jacobs
Description
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVAX Financial Timeline
Browse a chronological timeline of Novavax, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.40, while revenue estimate is $52.06m.
Earnings released on 6 May 2026
EPS came in at -$0.06 surpassing the estimated -$0.25 by +76.00%, while revenue for the quarter reached $139.51m , beating expectations by +74.82%.
Earnings released on 26 Feb 2026
EPS came in at $0.11 surpassing the estimated -$0.66 by +116.67%, while revenue for the quarter reached $147.14m , beating expectations by +63.77%.
Earnings released on 6 Nov 2025
EPS came in at -$0.62 surpassing the estimated -$1.08 by +42.59%, while revenue for the quarter reached $70.45m , beating expectations by +67.21%.
Earnings released on 6 Aug 2025
EPS came in at $0.62 surpassing the estimated -$0.07 by +985.71%, while revenue for the quarter reached $239.24m , beating expectations by +56.77%.
Earnings released on 8 May 2025
EPS came in at $2.93 surpassing the estimated $0.71 by +312.68%, while revenue for the quarter reached $666.66m , beating expectations by +93.88%.
Earnings released on 27 Feb 2025
EPS came in at -$0.51 surpassing the estimated -$0.75 by +32.00%, while revenue for the quarter reached $88.31m , beating expectations by +4.66%.
Earnings released on 12 Nov 2024
EPS came in at -$0.76 surpassing the estimated -$0.87 by +12.64%, while revenue for the quarter reached $84.51m , missing expectations by -7.05%.
Earnings released on 8 Aug 2024
EPS came in at $0.99 falling short of the estimated $1.64 by -39.63%, while revenue for the quarter reached $415.48m , missing expectations by -9.40%.
Earnings released on 10 May 2024
EPS came in at -$1.05 falling short of the estimated -$1.04 by -0.96%, while revenue for the quarter reached $93.86m , missing expectations by -7.22%.
Earnings released on 28 Feb 2024
EPS came in at -$1.44 falling short of the estimated -$0.49 by -193.88%, while revenue for the quarter reached $291.34m , missing expectations by -9.51%.
Earnings released on 9 Nov 2023
EPS came in at -$1.26 surpassing the estimated -$1.82 by +30.77%, while revenue for the quarter reached $22.06m , missing expectations by -93.14%.
Earnings released on 8 Aug 2023
EPS came in at $0.58 surpassing the estimated -$1.39 by +141.73%, while revenue for the quarter reached $424.43m , beating expectations by +77.47%.
Earnings released on 9 May 2023
EPS came in at -$3.41 falling short of the estimated -$3.38 by -0.89%, while revenue for the quarter reached $80.95m , missing expectations by -7.60%.
Earnings released on 28 Feb 2023
EPS came in at -$2.28 falling short of the estimated -$0.92 by -147.83%, while revenue for the quarter reached $287.83m , missing expectations by -24.88%.
Earnings released on 8 Nov 2022
EPS came in at -$2.15 falling short of the estimated $2.21 by -197.29%, while revenue for the quarter reached $734.58m , beating expectations by +25.30%.
Earnings released on 8 Aug 2022
EPS came in at -$6.53 falling short of the estimated $5.51 by -218.51%, while revenue for the quarter reached $185.93m , missing expectations by -78.47%.
Earnings released on 9 May 2022
EPS came in at $2.56 falling short of the estimated $2.69 by -4.83%, while revenue for the quarter reached $703.97m , missing expectations by -16.71%.
Earnings released on 28 Feb 2022
EPS came in at -$11.18 falling short of the estimated -$1.43 by -681.82%, while revenue for the quarter reached $222.20m , missing expectations by -33.03%.
Earnings released on 4 Nov 2021
EPS came in at -$4.31 falling short of the estimated -$4.04 by -6.68%, while revenue for the quarter reached $178.84m , missing expectations by -46.55%.
Earnings released on 5 Aug 2021
EPS came in at -$4.75 falling short of the estimated -$3.76 by -26.33%, while revenue for the quarter reached $298.02m , missing expectations by -23.17%.
NVAX Stock Performance
Access detailed NVAX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
